Cannabis, Cannabinoids and Health: A Review of the Risks
A September 2024 review in European Archives of Psychiatry and Clinical Neuroscience synthesizes the evidence on cannabis-related health risks. It covers the strongest signals — psychosis and schizophrenia, cognitive impairment in adolescent users, cannabis use disorder, respiratory effects from smoking, and adverse perinatal outcomes — and separates well-supported claims from weaker ones.
The review is notable for being a European clinical-psychiatry source rather than an American one, which is useful context: the same risk pattern shows up across health systems and regulatory environments.
This page is a draft. The full writeup will summarize each risk category's evidence grade and the review's clinical recommendations.